

(b) *Sponsor*. See 000006 in § 510.600(c) of this chapter.

(c) *Conditions of use*—(1) *Dogs*—(i) *Amount*. 0.5 to 1.0 milligram of enalapril maleate per kilogram of body weight per day.

(ii) *Indications for use*. Treatment of mild, moderate, and severe (modified New York Heart Association Class II, III, IV) heart failure in dogs.

(iii) *Limitations*. Use 0.5 milligram per kilogram once daily. In the absence of adequate clinical response within a 2-week period, use may be increased to twice daily (a total of 1.0 milligram per kilogram). Enalapril maleate is administered as conjunctive therapy with furosemide and digoxin in the treatment of dilated cardiomyopathy and furosemide with or without digoxin in the treatment of chronic valvular disease. The safety of enalapril for use in breeding dogs has not been established. Use in pregnant bitches is not recommended. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

[59 FR 17694, Apr. 14, 1994]

**§ 520.812 Enrofloxacin tablets.**

(a) *Specifications*. Each tablet contains either 5.7, 22.7, or 68.0 milligrams of enrofloxacin.

(b) *Sponsor*. See No. 000859 in § 510.600(c) of this chapter.

(c) *Conditions of use*—(1) *Amount* 2.5 mg/kg (1.13 mg/lb) of body weight twice daily.

(2)(i) *Indications for use*. Dogs for treatment of the following bacterial infections: dermal infections (wounds and abscesses) caused by susceptible strains of *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, and *Staphylococcus aureus*; respiratory infections (pneumonia, tonsillitis, rhinitis) caused by susceptible strains of *Escherichia coli* and *Staphylococcus aureus*; and urinary cystitis caused by susceptible strains of *Escherichia coli*, *Proteus mirabilis*, and *Staphylococcus aureus*.

(ii) *Cats* for treatment of the following bacterial infections: dermal infections (wounds and abscesses) caused by susceptible strains of *Pasteurella multocida*, *Staphylococcus aureus*, and *Staphylococcus epidermidis*.

(3) *Limitations*. Treatment should be continued for 2 to 3 days beyond cessation of clinical symptoms. Do not use for more than 10 days. Safe use in breeding female cats has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[54 FR 3444, Jan. 24, 1989, as amended at 55 FR 43327, Oct. 29, 1990]

**§ 520.816 Epsiprantel tablets.**

(a) *Specifications*. Each tablet contains either 12.5, 25, 50, or 100 milligrams of epsiprantel.

(b) *Sponsor*. See No. 000069 in § 510.600(c) of this chapter.

(c) *Conditions of use*—(1) *Dogs*—(i) *Amount*. 2.5 milligrams per pound of body weight.

(ii) *Indications for use*. Removal of canine cestodes *Dipylidium caninum* and *Taenia pisiformis*.

(2) *Cats*—(i) *Amount*. 1.25 milligrams per pound of body weight.

(ii) *Indications for use*. Removal of feline cestodes *D. caninum* and *T. taeniaeformis*.

(3) *Limitations*. For oral use only as a single dose. Do not use in animals less than 7 weeks of age. Safety of use in pregnant or breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[54 FR 50615, Dec. 8, 1989, as amended at 56 FR 50653, Oct. 8, 1991; 60 FR 55659, Nov. 2, 1995]

**§ 520.823 Erythromycin phosphate.**

(a) *Specifications*. Erythromycin phosphate is the phosphate salt of the antibiotic substance produced by the growth of *Streptomyces erythreus* or the same antibiotic substance produced by any other means. One gram of erythromycin phosphate is equivalent to 0.89 gram of erythromycin master standard.

(b) *Sponsor*. See No. 050604 in § 510.600(c) of this chapter.

(c) *Related tolerances*. See § 556.230 of this chapter.

(d) *Conditions of use*. It is used in drinking water as follows:

(1) *Broiler and replacement chickens*—(i) *Amount*. 0.500 gram per gallon.